极早产前常规产前硫酸镁暴露与无脑瘫生存率提高相关
这项基于澳大利亚和新西兰新生儿网络登记数据的回顾性队列研究纳入2012至2020年胎龄<30周的新生儿,评估产前硫酸镁暴露对无脑瘫或中重度功能损害生存的影响。在6763名2至3岁随访婴儿中,硫酸镁暴露与死亡或脑瘫风险降低(aRR 0.83,95%CI 0.74-0.93)及死亡或中重度功能损害风险降低(aRR 0.88,95%CI 0.81-0.97)相关。
要点
- 产前硫酸镁暴露与极早产/低出生体重儿无脑瘫生存率提高相关。
- 单胎妊娠中脑瘫风险降低更明显(aRR 0.68,95%CI 0.47-0.98)。
- 多胎妊娠中脑瘫风险降低未达统计学显著性(aRR 0.78,95%CI 0.59-1.05)。
核心结论
- 产前硫酸镁暴露在真实世界中与极早产和/或低出生体重儿无脑瘫或无中重度功能损害的生存率提高相关,支持持续和加强实施。
研究设计与样本
- 基于澳大利亚和新西兰新生儿网络登记数据的人群回顾性队列研究,纳入2012年1月1日至2020年12月31日出生、胎龄<30周的新生儿,出院结局分析共16582名。
- 2至3岁随访结局限于2017年12月31日前出生、胎龄<28周和/或体重<1000g的婴儿,共6763名,其中4353名(64%)暴露于硫酸镁。
- 采用逻辑回归分析并调整潜在混杂因素。
主要发现
- 在6763名婴儿中,硫酸镁暴露与死亡或脑瘫风险降低相关(调整相对风险0.83,95%CI 0.74-0.93)。
- 硫酸镁暴露与死亡或中重度功能损害风险降低相关(调整相对风险0.88,95%CI 0.81-0.97)。
- 单胎妊娠中脑瘫风险明显降低(调整相对风险0.68,95%CI 0.47-0.98)。
- 纳入多胎时脑瘫风险降低未达统计学显著性(调整相对风险0.78,95%CI 0.59-1.05)。
临床怎么用
- 对于极早产和/或低出生体重出生风险者,产前硫酸镁可用于胎儿神经保护,以增加无脑瘫生存机会。
- 单胎妊娠的神经保护获益证据更明确,多胎妊娠可结合个体情况评估使用。
局限性
- 为回顾性队列研究,可能存在残余混杂。
- 2至3岁随访仅限2017年底前出生且胎龄<28周和/或体重<1000g的婴儿,外推需谨慎。
- 多胎妊娠中脑瘫风险降低未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the last 2 decades, based on systematic reviews of randomized controlled trials, antenatal magnesium sulfate has been variably implemented internationally for fetal neuroprotection. OBJECTIVE: Our objective was to assess the effects of magnesium sulfate exposure prior to extremely preterm/low birthweight birth on survival without cerebral palsy or moderate to severe functional impairment in an Australian and New Zealand cohort. STUDY DESIGN: This population-based retrospective cohort study, using data from the Australian and New Zealand Neonatal Network registry, included neonates born from January 1, 2012 through December 31, 2020 at <30 weeks' gestation; due to data availability, 2 to 3 years of follow-up was restricted to those born through December 31, 2017 at <28 weeks' gestation and/or weighing <1000 g. Analyses were performed using logistic regression with adjustment for potential confounding. RESULTS: The cohort included 16,582 neonates for outcomes to hospital discharge. For primary outcomes at 2 to 3 years, among 6763 infants (4353 [64%] exposed to magnesium sulfate), exposure to magnesium sulfate was associated with a reduced risk of death or cerebral palsy (adjusted relative risk, 0.83; 95% confidence interval, 0.74-0.93) and of death or moderate to severe functional impairment (adjusted relative risk, 0.88; 95% confidence interval, 0.81-0.97). A clear reduction in cerebral palsy was observed for children born from singleton pregnancies (adjusted relative risk, 0.68; 95% confidence interval, 0.47-0.98). When multiples were included, the reduced risk of cerebral palsy was not statistically significant (adjusted relative risk, 0.78; 95% confidence interval, 0.59-1.05). CONCLUSION: Our large, binational study demonstrates real-world benefits of exposure to magnesium sulfate prior to extremely preterm and/or low birthweight birth, including increased survival without cerebral palsy or moderate to severe functional impairment, strongly supporting ongoing and enhanced implementation.
引用
- Shepherd E, Rumbold A, McIntyre S, et al. Antenatal magnesium sulfate prior to very preterm birth in routine care is associated with increased survival without cerebral palsy. Am J Obstet Gynecol. 2026. PMID: 42532419. doi:10.1016/j.ajog.2026.07.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。